Difference between revisions of "Buserelin (Suprefact)"
Jump to navigation
Jump to search
m |
m |
||
| Line 5: | Line 5: | ||
*[[Prostate cancer]] | *[[Prostate cancer]] | ||
| + | ==History of changes in EMA indication== | ||
| + | *EURD: 1984-08-16 | ||
==Also known as== | ==Also known as== | ||
*'''Code names:''' HOE 766, ICI 123215, S74-6766 | *'''Code names:''' HOE 766, ICI 123215, S74-6766 | ||
| Line 11: | Line 13: | ||
[[Category:Drugs]] | [[Category:Drugs]] | ||
[[Category:Prostate cancer medications]] | [[Category:Prostate cancer medications]] | ||
| + | |||
| + | [[Category:EMA approved in 1984]] | ||
[[Category:Stub]] | [[Category:Stub]] | ||
Revision as of 11:33, 13 June 2023
Mechanism of action
Gonadotropin-releasing hormone (GnRH) analog, inhibits pituitary gonadotropin secretion, which suppresses ovarian and testicular steroidogenesis.
Diseases for which it is used
History of changes in EMA indication
- EURD: 1984-08-16
Also known as
- Code names: HOE 766, ICI 123215, S74-6766
- Brand names: Bigonist, Etilamide, Profact, Receptal, Suprecur, Suprefact